ASCENTAGE PHARMA GROUP INTERNATIONAL Q1 FY2025 earnings call

• Business update: 2025 was a breakout year with over 90% revenue growth, dual commercial products, a commercial team close to 300 staff, and major R&D milestones like SOVA approval, Glora - 4 and Polaris 1 phase III registration trial clearances. - R&D highlights: World - class, innovative, late - stage pipeline with seven novel compounds, including Orenbatinet, Lisovacast, and novel BDK degrader APG3288. - Commercial update: Built a large commercial scale in China with dual products approved, over 270 - strong commercial team covering 1,500 hospitals and 800 DDP pharmacies.

In 2025, total revenue was over $82.1 million, a 90%+ growth. Olorambatinib sales were $62.2 million, 81% year - over - year growth, representing 81% of total revenue. Lisopracase had first five - month sales of $10.1 million. R&D expense increased from $130 million to $163 million, S&D expenses increased from $27 million to $51 million. Year - end cash balance was $353.2 million.

• Clinical development in 2026: Major focus on advanced enrollment for Glora and Glora 4 registration trials, Polaris 2 and Polaris 1 trials. Push forward APG3288 global phase one study and ED inhibitor ABG591A in oncology and anemia. - Commercial front: Continue to drive sales growth for Olorambatinib and Lisopracase to tier one hospitals and more pharmacies, and aim for NRDL coverage in China for Lisopracase in 2026.

Q: Brian Cheng from JP Morgan asked about enrollment in registrational studies and dose indication milestones.

A: Dr. Yang responded on enrollment in Glora IV MDS and Polaris 1 studies, and the potential of the trials.

Q: Byron Amin from Piper Sunder asked about market share of Olorambatinib in China and growth rate in 2026.

A: Dr. Yang discussed market share and future growth drivers.

Q: Gregory Renzer from Tourist Securities asked about Olorambatinib's profile and progress in second line or earlier lines in CML.

A: Dr. Yang answered on the drug's profile and progress.

Q: Jeet Mukherjee from BTIG asked about China opportunity and BTK degrader's non - oncology opportunities.

A: Dr. Yang answered on hospital coverage target and non - oncology potential.

Q: Matthew Beigler from OCWO asked about CLL market and Ascentage's favor with BTK - degrader and Lisopracase.

A: Dr. Yang responded on the CLL market and combination potential.

Q: Christopher Leao from Lucid Capital Markets asked about Takeda's go - no - go decision and Lesopracase's partnership.

A: Dr. Yang answered on partnership and commercialization plans.

Q: Michael King from Rodman and Renshaw asked about market dynamics of allosteric inhibitors in CML space.

A: Dr. Yang discussed market dynamics and competition